News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Roche Holding AG Seeks to Broaden Use of Cancer Drug MabThera
March 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Swiss drugmaker Roche Holding AG (ROG.VX) is looking to broaden the use of its cancer drug MabThera in non-Hodgkin's lymphoma in Europe, underscoring the strength of its position in oncology.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
Drug Development
The Gap Between the Administration’s Pro-Innovation Words and Policy
July 14, 2025
·
6 min read
·
Lori Ellis
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
July 14, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
July 14, 2025
·
1 min read
·
Tristan Manalac
Complete response letters
Capricor Plunges on FDA Rejection of DMD Cell Therapy
July 11, 2025
·
3 min read
·
Tristan Manalac